Insight, China's Pharmaceutical Industry

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Simcere Pharmaceutical Group Limited (HKG: 2096) announced it has received clinical trial approval from China’s...

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026

Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus...

Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Fineline Cube May 6, 2026

Senhwa Biosciences, Inc. (TPE: 6492) announced on May 5, 2026, the initiation of a global,...

Company

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Fineline Cube May 6, 2026

Amgen (NASDAQ: AMGN) announced on May 4, 2026, an additional $300 million investment in its...

Company

Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance

Fineline Cube May 6, 2026

Pfizer Inc. (NYSE: PFE) reported first quarter 2026 financial results on May 5, 2026, with...

Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026

The National Health Commission (NHC) of China has implemented the Guiding Principles for Defining Biomedical...

Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026

UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics...

Company Drug

AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data

Fineline Cube May 6, 2026

AstraZeneca plc (NYSE: AZN) announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs...

Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026

SiranBio, a Suzhou-based siRNA drug developer, announced a strategic licensing agreement with GlaxoSmithKline plc (GSK;...

Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Fineline Cube Apr 30, 2026

Beijing Avistone Biotechnology Co., Ltd. announced that its self-developed EGFR exon 20 insertion (ex20ins) inhibitor,...

Company

GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength

Fineline Cube Apr 30, 2026

GE Healthcare Technologies Inc. (NASDAQ: GEHC) reported first-quarter 2026 financial results with revenues of USD...

Company

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

Fineline Cube Apr 30, 2026

GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced a major organizational restructuring aimed at driving stronger...

Others

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength

Fineline Cube Apr 30, 2026

AstraZeneca PLC (NYSE: AZN) reported first-quarter 2026 financial results with total revenue of USD 15.288...

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S....

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Fineline Cube Apr 30, 2026

Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD...

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093...

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026

Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under...

Company

AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength

Fineline Cube Apr 30, 2026

AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of...

Company

3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal

Fineline Cube Apr 30, 2026

3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to...

Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026

Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an...

Insight, China's Pharmaceutical Industry

Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon

Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations

Sihuan Pharmaceutical and dProtein Biotechnology Form AI-Powered Medical Aesthetics Joint Venture

Salvectors Receives NMPA Clinical Approval for YB1-X7, World’s First Oncolytic Salmonella Therapy for Advanced Solid Tumors

D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026

Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength

3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

You Missed

D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026

Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026

CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026

GenFleet’s GFS202A Becomes World’s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026